Physician

Charles L Bane, MD

According to 2025 Medicare claims, Charles Bane, MD (NPI: 1730134933) practices hematology/oncology in the Dayton-Kettering-Beavercreek, OH market, with the plurality of this provider's patient population coming from Montgomery, OH. This provider's primary affiliated billing organization is DAYTON PHYSICIANS, LLC (NPI: 1902844947; TIN: 203130844) and primary practice location at 45415-1333. Bane is affiliated with the Health Centers of Ohio ACO LLC (ACO ID: A5411), participating under the MSSP model.

Bane's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 782 traditional Medicare patients, billed 100,552 HCPCS/CPT codes, and received $2,346,822 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 3,979 prescription claims across 530 beneficiaries totaling $5,093,094 in drug costs, led by Brukinsa (Zanubrutinib). DME data shows 12 claims. Open Payments data shows 197 records totaling $302,038. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $987,738 to $2,346,822. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,954,245 to $5,093,094. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $5,178 to $1,347.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	710	94,328	$987,738
2016	743	90,113	$1,250,320
2017	775	114,872	$1,443,430
2018	901	98,448	$1,594,130
2019	942	137,041	$1,974,755
2020	757	116,522	$2,150,252
2021	772	154,073	$2,865,606
2022	774	89,857	$1,481,156
2023	728	110,412	$1,847,706
2024	782	100,552	$2,346,822

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	388	2,214	$1,954,245
2016	399	2,145	$2,277,979
2017	368	1,978	$1,908,027
2018	385	2,457	$3,415,403
2019	336	2,320	$3,518,709
2020	358	2,628	$3,099,431
2021	378	2,718	$4,223,332
2022	347	1,865	$3,465,325
2023	464	3,150	$4,621,220
2024	530	3,979	$5,093,094

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	66	$6,052
2016	11	70	$6,115
2017	N/R	92	$10,758
2018	N/R	53	$6,127
2019	N/R	14	$741
2020	N/R	65	$3,325
2021	N/R	55	$4,774
2022	N/R	N/R	N/R
2023	N/R	11	$354
2024	N/R	12	$189

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	107	265	$131
96413	Administration of chemotherapy into vein, 1 hour or less	75	219	$97
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	351	1,133	$92
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	279	342	$57
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	407	1,454	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Brukinsa	Zanubrutinib	54	1,620	$789,832
Lenalidomide	Lenalidomide	54	1,484	$726,817
Cabometyx	Cabozantinib S-Malate	28	840	$690,713
Revlimid	Lenalidomide	30	805	$401,613
Ibrance	Palbociclib	19	532	$288,502

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	12	$189

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	157	$3,061	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	40	$298,976	Daiichi Sankyo Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Charles L. Bane, MD?

Tedicare shows public-source Medicare data for Charles L. Bane, MD (NPI 1730134933), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Charles L. Bane, MD have ACO affiliation data?

Charles L. Bane, MD is shown with ACO affiliation data for Health Centers of Ohio ACO LLC (MSSP, ACO ID A5411).

What billing organization is linked to Charles L. Bane, MD?

Charles L. Bane, MD is linked to DAYTON PHYSICIANS, LLC (billing NPI 1902844947) in the available physician profile data.

Does Charles L. Bane, MD have Open Payments data?

Charles L. Bane, MD has 197 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.